It develops in response to tumor-derived factors and releases IL10, IL12, TNFα, TNFβ, VEGF, CCL20, CCL22, and MMP9, thereby supporting tumor growth and metastases and acting as an immunosuppressant. Here, CCL22 is linked to neoplasm.